Pharmaceuticals

Danyelza Market Expansion Forecast Reaching $5.28 Billion By 2030 At 6.1% CAGR

May 5, 2026May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Danyelza Market Compare Between 2026 And 2030?

Historic expansion was driven by unfavorable results in recurrent neuroblastoma, progress in monoclonal antibody treatments, the authorization of orphan drugs, focused expertise in pediatric cancer care, and the clinical effectiveness of GD2 targeting.

The projected expansion within the forecast period is primarily driven by an uptick in pediatric cancer trials, the broadening of immuno-oncology pipelines, enhanced accessibility to specialty cancer centers, favorable reimbursement policies, and increased awareness of rare cancers.

Significant trends expected throughout the forecast period include the increasing adoption of targeted immunotherapy, greater utilization of GD2-directed treatments, the expansion of therapeutic options in pediatric oncology, a rise in combination cancer treatment approaches, and a stronger emphasis on managing refractory and relapsed cancers.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20031&type=smp

What Key Drivers Are Fueling The Growth Of The Danyelza Market?

The rising occurrence of pediatric cancers is anticipated to fuel the expansion of the danyelza market in the foreseeable future. Cancers found in children and teenagers, known as pediatric cancers, encompass a range of types, including leukemia, brain tumors, neuroblastoma, and lymphomas. This growing incidence of pediatric cancers stems from several factors, such as improvements in diagnostic methods, exposure to environmental elements, genetic predispositions, and the lasting impacts of cancer therapies. Danyelza (naxitamab) functions as a targeted immunotherapy designed to lower the frequency of pediatric cancers through its effective treatment of high-risk neuroblastoma. When used alongside other treatments, it has demonstrated enhanced survival outcomes and slowed disease progression in young patients battling this aggressive form of cancer. As an illustration, in October 2024, information from the Cancer Council, an Australia-based non-profit organization, indicated that in 2022, approximately 93 children aged 0-14 years in Australia succumbed to cancer. Additionally, Victoria recorded 206 cancer diagnoses in children under 15 and 263 in individuals aged 15-24. By 2023, the number of living individuals who had received a cancer diagnosis during their childhood or adolescence reached 6,197 males and 5,523 females. Consequently, the expanding occurrence of pediatric cancers is a key factor propelling the expansion of the danyelza market.

How Are Different Segments Classified In The Danyelza Market Segment Analysis?

The danyelza market covered in this report is segmented –

1) By Indication: Neuroblastoma, Osteosarcoma And Other GD2-Positive Cancers

2) By Treatment Type: Monotherapy, Combination Therapy

3) By End User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Center

What Emerging Trends Are Seen In The Danyelza Market?

Prominent companies in the danyelza market are concentrating on creating advanced formulations, such as targeted immunotherapy, to expand treatment possibilities and enhance patient results. Targeted immunotherapy denotes therapies that use substances to precisely target and assault cancer cells by focusing on specific proteins or markers, like GD2 in neuroblastoma, thereby allowing the immune system to destroy malignant cells. For example, in May 2023, Y-mAbs Therapeutics Inc., a US-based biotech firm, secured marketing authorization from Brazil’s Agência Nacional de Vigilância Sanitária for Danyelza (naxitamab-gqgk) 40 mg/10 mL injection, a therapy for high-risk neuroblastoma. Danyelza is a recombinant humanized monoclonal antibody that targets GD2, a ganglioside common in neuroectoderm-derived tumors and sarcomas, and its creation was attributed to Memorial Sloan Kettering Cancer Center under an exclusive license to Y-mAbs.

Who Are The Companies Driving Activity In The Danyelza Market?

Major companies operating in the danyelza market are Y-mAbs Therapeutics Inc.

Get The Full Danyelza Market Report:

https://www.thebusinessresearchcompany.com/report/danyelza-global-market-report

Which Region Is The Top Contributor To The Danyelza Market By Share?

North America was the largest region in the danyelza market in 2025. The regions covered in the danyelza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Danyelza Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/danyelza-global-market-report

Browse Through More Reports Similar to the Global Danyelza Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Direct Selling Market Report 2026

https://www.thebusinessresearchcompany.com/report/direct-selling-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795